Longer follow-up of the phase 2 LUNAR trial showed a 62% lower risk of progression, additional hormone therapy or death with 177Lu-PNT2002 plus radiation.
A study found that sentinel lymph node biopsy rarely missed remaining cancer in patients with locally advanced breast cancer whose lymph nodes responded to chemotherapy before surgery.
Alternating two long-used bladder treatments cleared cancer in 24 of 25 patients whose disease had returned after BCG, an early study found. A larger trial comparing the approach with BCG alone is now enrolling.
The FDA has cleared TumorSight Risk, software that uses a patient's existing breast MRI, pathology and clinical information to estimate the chance that early HR-positive, HER2-negative breast cancer will come back within five and 10 years.